During the last session, T2 Biosystems Inc. (NASDAQ:TTOO)’s traded shares were 1.71 million, with the beta value of the company hitting 0.63. At the end of the trading day, the stock’s price was $0.18, reflecting an intraday gain of 4.76% or $0.01. The 52-week high for the TTOO share is $1.27, that puts it down -605.56 from that peak though still a striking 16.67% gain since the share price plummeted to a 52-week low of $0.15. The company’s market capitalization is $28.91M, and the average trade volume was 1.95 million shares over the past three months.
T2 Biosystems Inc. (TTOO) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 1.30. TTOO has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.09.
T2 Biosystems Inc. (NASDAQ:TTOO) trade information
T2 Biosystems Inc. (TTOO) registered a 4.76% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 4.76% in intraday trading to $0.18 this Thursday, 06/23/22, hitting a weekly high. The stock’s 5-day price performance is 4.76%, and it has moved by -15.19% in 30 days. Based on these gigs, the overall price performance for the year is -85.52%.
The consensus price target of analysts on Wall Street is $0.88, which implies an increase of 79.55% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $0.65 and $1.00 respectively. As a result, TTOO is trading at a discount of -455.56% off the target high and -261.11% off the low.
T2 Biosystems Inc. (TTOO) estimates and forecasts
Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to shrink -12.50% this quarter and then jump 12.50% in the quarter after that. In the rating firms’ projections, revenue will increase 4.50% compared to the previous financial year.
Revenue for the current quarter is expected to be $6.87 million as predicted by 3 analyst(s). Meanwhile, a consensus of 3 analyst(s) estimates revenue growth to $7.4 million by the end of Sep 2022. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $6.69 million and $5.7 million respectively. In this case, analysts expect current quarter sales to grow by 2.60% and then jump by 29.80% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 31.80%. While earnings are projected to return 19.60% in 2022.
T2 Biosystems Inc. is due to release its next quarterly earnings between March 02 and March 07. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
T2 Biosystems Inc. (NASDAQ:TTOO)’s Major holders
T2 Biosystems Inc. insiders own 4.73% of total outstanding shares while institutional holders control 10.64%, with the float percentage being 11.17%. Vanguard Group, Inc. (The) is the largest shareholder of the company, while 86 institutions own stock in it. As of Dec 30, 2021, the company held over 6.68 million shares (or 3.90% of all shares), a total value of $3.45 million in shares.
The next largest institutional holding, with 6.68 million shares, is of Vanguard Group, Inc. (The)’s that is approximately 3.90% of outstanding shares. At the market price on Dec 30, 2021, these shares were valued at $3.45 million.
Also, the Mutual Funds coming in first place with the largest holdings of T2 Biosystems Inc. (TTOO) shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. Data provided on Dec 30, 2021 indicates that Vanguard Total Stock Market Index Fund owns about 4.09 million shares. This amounts to just over 2.39 percent of the company’s overall shares, with a $2.11 million market value. The same data shows that the other fund manager holds slightly less at 2.16 million, or about 1.26% of the stock, which is worth about $1.12 million.